Literature DB >> 29080946

Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer.

Hideyuki Morimoto1, Yushi Fujiwara2, Shigeru Lee2, Kosuke Amano3, Masako Hosono3, Yukio Miki3, Harushi Osugi4.   

Abstract

PURPOSE: We evaluated the effectiveness of neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy for cT4 esophageal cancer or lymph node metastases (LNM) invading adjacent structures.
MATERIALS AND METHODS: We retrospectively evaluated 42 consecutive patients with thoracic esophageal cancer who underwent CRT followed by esophagectomy between 2008 and 2013. All were initially considered to be unresectable because of cT4 (n = 32) disease or LN invasion (n = 10). Radiotherapy was administered at 41.4 Gy/23 fr with concurrent chemotherapy. At completion of CRT, restaging was performed using computed tomography (CT).
RESULTS: All cT4 tumors were downstaged, LNM invading to adjacent structures were considered to be released, and subtotal esophagectomy was performed. The median follow-up period was 42 months. The curative resection (R0) rate was 94% in cT4 group and 70% in LN invasion group. The 3-year overall survival (OS) and 3-year locoregional control (LRC) rates were 65-80% in the cT4 group and 50-67% in LN invasion group, respectively.
CONCLUSIONS: The cT4 group showed good rates of R0, OS, and LRC. Surgical resection should be an effective option when downstaging is achieved by CRT for patients with initially inoperable thoracic esophageal cancer.

Entities:  

Keywords:  Chemoradiotherapy; Esophageal cancer; Esophagectomy; Neoadjuvant therapy; cT4

Mesh:

Year:  2017        PMID: 29080946     DOI: 10.1007/s11604-017-0693-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  25 in total

1.  Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs.

Authors:  K Ikeda; K Ishida; N Sato; K Koeda; K Aoki; Y Kimura; T Iwaya; S Ogasawara; S Iijima; R Nakamura; N Uesugi; C Maesawa; K Saito
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

2.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

3.  Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma.

Authors:  T Noguchi; H Moriyama; S Wada; S Takeno; M Wakisaka; H Mori; Y Uchida
Journal:  Dis Esophagus       Date:  2003       Impact factor: 3.429

4.  Questionable resection for carcinoma of the esophagus involving the trachea, bronchus and/or aorta--a comparative and multivariate analysis.

Authors:  H Fujita; T Kakegawa; H Kawahara; H Yamana; I Shima; H Rikitake; M Hyodo; S Tsugane
Journal:  Kurume Med J       Date:  1992

Review 5.  Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer.

Authors:  E F W Courrech Staal; B M P Aleman; H Boot; M-L F van Velthuysen; H van Tinteren; J W van Sandick
Journal:  Br J Surg       Date:  2010-10       Impact factor: 6.939

6.  Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.

Authors:  Giovanni de Manzoni; Corrado Pedrazzani; Felice Pasini; Marco Bernini; Anna Maria Minicozzi; Simone Giacopuzzi; Antonio Grandinetti; Claudio Cordiano
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

7.  Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Yasumasa Nishimura; Keiichi Jingu; Satoshi Itasaka; Yoshiharu Negoro; Yuji Murakami; Katsuyuki Karasawa; Gen Kawaguchi; Fumiaki Isohashi; Masao Kobayashi; Yoshiyuki Itoh; Takuro Ariga
Journal:  Int J Clin Oncol       Date:  2015-07-16       Impact factor: 3.402

8.  Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).

Authors:  Katsuhiko Higuchi; Shouko Komori; Satoshi Tanabe; Chikatoshi Katada; Mizutomo Azuma; Hiromichi Ishiyama; Tohru Sasaki; Kenji Ishido; Natsuya Katada; Kazushige Hayakawa; Wasaburo Koizumi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-24       Impact factor: 7.038

9.  Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus.

Authors:  M Yano; T Tsujinaka; H Shiozaki; M Inoue; Y Doki; M Yamamoto; E Tanaka; T Inoue; M Monden
Journal:  J Surg Oncol       Date:  1999-01       Impact factor: 3.454

Review 10.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.